Atara Biotherapeutics Inc (NASDAQ:ATRA) EVP Christopher Haqq sold 775 shares of the stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $33.81, for a total value of $26,202.75. Following the transaction, the executive vice president now directly owns 285,580 shares of the company’s stock, valued at $9,655,459.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Christopher Haqq also recently made the following trade(s):

  • On Tuesday, September 25th, Christopher Haqq sold 31,500 shares of Atara Biotherapeutics stock. The shares were sold at an average price of $40.17, for a total value of $1,265,355.00.

Shares of NASDAQ:ATRA traded up $2.01 during trading on Thursday, hitting $35.85. The company had a trading volume of 344,303 shares, compared to its average volume of 699,982. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -8.96 and a beta of 2.59. Atara Biotherapeutics Inc has a one year low of $13.20 and a one year high of $54.45.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by ($0.16). On average, analysts expect that Atara Biotherapeutics Inc will post -4.82 earnings per share for the current year.

Several large investors have recently bought and sold shares of ATRA. California State Teachers Retirement System lifted its stake in shares of Atara Biotherapeutics by 18.9% in the 1st quarter. California State Teachers Retirement System now owns 50,110 shares of the biotechnology company’s stock valued at $1,954,000 after purchasing an additional 7,951 shares during the last quarter. Principal Financial Group Inc. purchased a new stake in shares of Atara Biotherapeutics in the first quarter worth approximately $214,000. Bank of Montreal Can purchased a new stake in shares of Atara Biotherapeutics in the second quarter worth approximately $180,000. Assenagon Asset Management S.A. raised its holdings in shares of Atara Biotherapeutics by 73.2% in the second quarter. Assenagon Asset Management S.A. now owns 237,668 shares of the biotechnology company’s stock worth $8,734,000 after buying an additional 100,432 shares during the period. Finally, Amalgamated Bank purchased a new stake in shares of Atara Biotherapeutics in the second quarter worth approximately $228,000.

ATRA has been the subject of several analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Atara Biotherapeutics in a research note on Friday, August 3rd. BidaskClub raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 24th. Finally, Zacks Investment Research lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 9th. Three research analysts have rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $47.80.

TRADEMARK VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2018/11/15/insider-selling-atara-biotherapeutics-inc-atra-evp-sells-775-shares-of-stock.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Story: What is the Dividend Aristocrat Index?

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.